India, March 12 -- image credit- shutterstock

Alkem Laboratories has announced the launch of Empanorm in India, a generic version of empagliflozin, for the treatment of type-2 diabetes mellitus, chronic kidney disease (CKD), and chronic heart failure (HF). The product is priced approximately 80% lower than the innovator drugs, making it more accessible to patients.

Alkem's Empanorm is bioequivalent to the innovator products and features an anti-counterfeit security band on the packaging. It also includes patient education materials in Hindi and English, along with QR codes providing additional information on diabetes, heart failure, and CKD in 11 languages. To enhance patient convenience, Alkem has introduced the medicine in a smaller t...